

**Akers Biosciences, Inc.**  
**Issue of Shares**

Akers Biosciences, Inc. (“the Company”) today announces it has issued 136,787 shares (“Common Shares”) to Brittany Capital Management Limited (“Brittany”), a fund advised by Southridge Capital Management LLC (“SCM”). The transaction results from an agreement (the “Agreement”) entered into by the Company, SCM and Brittany at the end of January 2007 under which SCM provided \$2.2 million of convertible debt to the Company, at an annual interest rate of 9 per cent. Under the terms of the Agreement, SCM is entitled to convert tranches of the debt into Common Shares up until 31 July 2007. The funds raised as a result of the Agreement are being used by the Company to exploit their current commercial opportunities.

The transaction represents the conversion by Brittany of \$100,000 of principal of the debenture, along with accrued interest of \$4,019. The transaction provides \$104,019 of permanent equity through the issue of 136,787 shares of common stock (“Common Shares”), at no par value, at \$.76 (£0.39 per share).

There remains approximately \$2.1 million of principal of this debenture outstanding to Brittany.

For the purpose of this announcement, the exchange rate used is £1:\$1.9595.

Application has been made to the London Stock Exchange for the 136,787 Common Shares to be admitted to trading, such admission expected to take place on 9 February 2006.

Contact

Paul B. Freedman – 001 856 848 2116.

END